FluidForm Bio

Executive Summary

FluidForm Bio is a private regenerative medicine and medical devices company headquartered in Marlborough, Massachusetts, founded in 2017. The company has developed a proprietary platform that builds living human tissue using only cells and proteins, eliminating the need for synthetic scaffolds or exogenous materials. By integrating personalized medicine, synthetic and computational biology, advanced materials, bioprinting, and artificial intelligence, FluidForm Bio can transform patient-specific data into functional human tissues. This approach addresses critical unmet needs in tissue engineering, particularly for applications such as organ transplantation, drug testing, and disease modeling. The technology has the potential to overcome current limitations in tissue vascularization, scalability, and immunocompatibility. FluidForm Bio operates at the intersection of multiple cutting-edge fields, positioning it as a pioneer in the next generation of bioprinting. The company has not publicly disclosed its total funding or valuation, but its presence in the competitive Boston-area biotech ecosystem suggests active research and development. As an early-stage private firm, FluidForm Bio faces typical challenges in manufacturing scalability, regulatory pathway, and clinical translation. However, its novel approach to scaffold-free tissue fabrication could differentiate it in the rapidly growing regenerative medicine market, which is projected to exceed $100 billion by 2030. Key near-term milestones include potential partnerships with pharmaceutical companies for drug screening platforms and further validation of its technology in preclinical models.

Upcoming Catalysts (preview)

• Q1 2027Series A or B Funding Announcement70% success
• Q4 2026Strategic Partnership with a Major Pharma Company for Drug Screening Applications50% success
• Q3 2026Preclinical Proof-of-Concept Data in a High-Impact Journal or Conference80% success